{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:47:49Z","timestamp":1790790469391,"version":"4.1.0"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010032","name":"Foundation of Shanghai Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["15GWZK0901"],"award-info":[{"award-number":["15GWZK0901"]}],"id":[{"id":"10.13039\/501100010032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0440-9","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T11:59:11Z","timestamp":1542715151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma"],"prefix":"10.1136","volume":"6","author":[{"given":"Bin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"issue":"10053","key":"440_CR1","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(16)31460-X","volume":"388","author":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE)","year":"2016","unstructured":"Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE). 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1603\u201358.","journal-title":"Lancet"},{"issue":"4","key":"440_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. Jama Oncol. 2017;3(4):524\u201348.","journal-title":"Jama Oncol"},{"issue":"9","key":"440_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrurol.2014.194","volume":"11","author":"JR Bhatt","year":"2014","unstructured":"Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol. 2014;11(9):517\u201325.","journal-title":"Nat Rev Urol"},{"issue":"9","key":"440_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184423","volume":"12","author":"B Amzal","year":"2017","unstructured":"Amzal B, Fu S, Meng J, Lister J, Karcher H. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS One. 2017;12(9):e0184423.","journal-title":"PLoS One"},{"issue":"19","key":"440_CR5","doi-asserted-by":"publisher","first-page":"27044","DOI":"10.18632\/oncotarget.7395","volume":"7","author":"X Sheng","year":"2016","unstructured":"Sheng X, Chi Z, Cui C, et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016;7(19):27044\u201354.","journal-title":"Oncotarget"},{"issue":"3","key":"440_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fernandez-Pello","year":"2017","unstructured":"Fernandez-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71(3):426\u201336.","journal-title":"Eur Urol"},{"issue":"2","key":"440_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118022","volume":"10","author":"W Gu","year":"2015","unstructured":"Gu W, Zhu Y, Wang H, et al. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series. PLoS One. 2015;10(2):e0118022.","journal-title":"PLoS One"},{"issue":"45","key":"440_CR8","doi-asserted-by":"crossref","first-page":"73068","DOI":"10.18632\/oncotarget.12230","volume":"7","author":"T Zhang","year":"2016","unstructured":"Zhang T, Xie J, Arai S, et al. The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7(45):73068\u201379.","journal-title":"Oncotarget"},{"issue":"6382","key":"440_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"6","key":"440_CR10","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.18632\/oncotarget.2980","volume":"6","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479\u201392.","journal-title":"Oncotarget"},{"issue":"6","key":"440_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1634\/theoncologist.2016-0435","volume":"22","author":"A Bamias","year":"2017","unstructured":"Bamias A, Escudier B, Sternberg CN, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist. 2017;22(6):667\u201379.","journal-title":"Oncologist"},{"issue":"14","key":"440_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. New Engl J Med. 2018;378(14):1277\u201390.","journal-title":"New Engl J Med"},{"issue":"3","key":"440_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/14737167.2018.1439740","volume":"18","author":"Panagiotis Petrou","year":"2018","unstructured":"Petrou P. A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):255\u201365.","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"1","key":"440_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/0272989X15585121","volume":"36","author":"EH Elbasha","year":"2016","unstructured":"Elbasha EH, Chhatwal J. Theoretical foundations and practical applications of within-cycle correction methods. Med Decis Mak. 2016;36(1):115\u201331.","journal-title":"Med Decis Mak"},{"key":"440_CR15","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman O. Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncol. 2017;13(22):1967\u201380.","DOI":"10.2217\/fon-2017-0175"},{"issue":"4","key":"440_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.eururo.2017.07.041","volume":"73","author":"M Sarfaty","year":"2018","unstructured":"Sarfaty M, Leshno M, Gordon N, et al. Cost effectiveness of Nivolumab in advanced renal cell carcinoma. Eur Urol. 2018;73(4):628\u201334.","journal-title":"Eur Urol"},{"issue":"3","key":"440_CR17","first-page":"276","volume":"51","author":"J Xiao","year":"2017","unstructured":"Xiao J, Sun JF, Wang QQ, Qi X, Yao HY. Health economic evaluation reporting guideline and application status. Zhonghua Yu Fang Yi Xue Za Zhi. 2017;51(3):276\u201380.","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"issue":"10","key":"440_CR18","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.jtho.2017.07.013","volume":"12","author":"Christos Chouaid","year":"2017","unstructured":"Chouaid C, Luciani L, LeLay K, et al. Cost-effectiveness analysis of Afatinib versus Gefitinib for first-line treatment of advanced EGFR-mutated advanced non-small cell lung cancers. J Thorac Oncol. 2017;12(10):1496\u2013502.","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"440_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22060","volume":"22","author":"SJ Edwards","year":"2018","unstructured":"Edwards SJ, Wakefield V, Cain P, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22(6):1\u2013278.","journal-title":"Health Technol Assess"},{"issue":"24","key":"440_CR20","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1200\/JCO.2007.13.2662","volume":"26","author":"E Remak","year":"2008","unstructured":"Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26(24):3995\u20134000.","journal-title":"J Clin Oncol"},{"issue":"3","key":"440_CR21","doi-asserted-by":"publisher","first-page":"e32530","DOI":"10.1371\/journal.pone.0032530","volume":"7","author":"B Wu","year":"2012","unstructured":"Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One. 2012;7(3):e32530.","journal-title":"PLoS One"},{"key":"440_CR22","unstructured":"US Department of Labor. Calculators. https:\/\/www.bls.gov\/data\/inflation_calculator.htm . Accessed 30 Mar 2018."},{"issue":"7","key":"440_CR23","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40273-018-0630-9","volume":"36","author":"Irina A. Tikhonova","year":"2018","unstructured":"Tikhonova IA, Huxley N, Snowsill T et al. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Pharmacoeconomics. 2018;36(7):837\u201351.","journal-title":"PharmacoEconomics"},{"key":"440_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-018-0095-8","volume":"7","author":"C McCrea","year":"2018","unstructured":"McCrea C, Johal S, Yang S, Doan J. Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States. Exp Hematol Oncol. 2018;7:4.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"440_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/jjco\/hyv045","volume":"45","author":"H Akaza","year":"2015","unstructured":"Akaza H, Naito S, Ueno N, et al. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol. 2015;45(6):576\u201383.","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"440_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10198-018-0964-4","volume":"19","author":"Yang Meng","year":"2018","unstructured":"Meng Y, Hertel N, Ellis J, et al. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. Eur J Health Econ. 2018;19(8):1163\u201372.","journal-title":"The European Journal of Health Economics"},{"issue":"1","key":"440_CR27","first-page":"46","volume":"21","author":"TE Delea","year":"2015","unstructured":"Delea TE, Amdahl J, Diaz J, Nakhaipour HR, Hackshaw MD. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015;21(1):46\u201354 54a-b.","journal-title":"J Manag Care Spec Pharm"},{"key":"440_CR28","unstructured":"RED BOOK Online. 2017. http:\/\/www.micromedexsolutions.com \/. Accessed 24 Oct 2017."},{"issue":"1","key":"440_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1524-4733.2009.00617.x","volume":"13","author":"M Hoyle","year":"2010","unstructured":"Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health. 2010;13(1):61\u20138.","journal-title":"Value Health"},{"issue":"5","key":"440_CR30","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1464-410X.2010.09957.x","volume":"108","author":"A Benedict","year":"2011","unstructured":"Benedict A, Figlin RA, Sandstrom P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011;108(5):665\u201372.","journal-title":"BJU Int"},{"key":"440_CR31","first-page":"347","volume":"5","author":"HJ Henk","year":"2013","unstructured":"Henk HJ, Chen C, Benedict A, Sullivan J, Teitelbaum A. Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population. Clinicoecon Outcomes Res. 2013;5:347\u201354.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"440_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3111\/13696998.2014.985789","volume":"18","author":"A Perrin","year":"2015","unstructured":"Perrin A, Sherman S, Pal S, et al. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ. 2015;18(3):200\u20139.","journal-title":"J Med Econ"},{"issue":"1","key":"440_CR33","first-page":"37","volume":"21","author":"RN Hansen","year":"2015","unstructured":"Hansen RN, Hackshaw MD, Nagar SP, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm. 2015;21(1):37\u201344 44a-d.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"440_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","volume":"27","author":"SY Liou","year":"2007","unstructured":"Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007;27(6):381\u201396.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"440_CR35","doi-asserted-by":"publisher","first-page":"e0175920","DOI":"10.1371\/journal.pone.0175920","volume":"12","author":"J Amdahl","year":"2017","unstructured":"Amdahl J, Diaz J, Sharma A, et al. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PLoS One. 2017;12(6):e0175920.","journal-title":"PLoS One"},{"key":"440_CR36","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368.","DOI":"10.1200\/JCO.2017.77.6385"},{"issue":"Suppl 2","key":"440_CR37","first-page":"45","volume":"73","author":"T Isobe","year":"2015","unstructured":"Isobe T, Hayashi M, Tsubata Y. Clinical practice guidelines for the adverse events in medical oncology. Nihon Rinsho. 2015;73(Suppl 2):45\u201350.","journal-title":"Nihon Rinsho"},{"issue":"1","key":"440_CR38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjc.6605417","volume":"102","author":"G Mickisch","year":"2010","unstructured":"Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80\u20136.","journal-title":"Br J Cancer"},{"issue":"9","key":"440_CR39","first-page":"63","volume":"9","author":"Q Jia","year":"2016","unstructured":"Jia Q. Cost-effectiveness of durogesic, morphine sulphate controlled-release tablets and oxycontin for advanced cancerous pain. Chinese Journal of Clinical Rational Drug Use. 2016;9(9):63\u20134.","journal-title":"Chinese Journal of Clinical Rational Drug Use"},{"key":"440_CR40","first-page":"68","volume":"07","author":"T Yu-mei","year":"2017","unstructured":"Yu-mei T, Fang-zhan G, Hong-wu Z, et al. The effectiveness of Chinese herbal fumigation for hand-foot syndrome caused by capecitabine. Qinghai Medical Journal. 2017;07:68\u201370.","journal-title":"Qinghai Medical Journal"},{"issue":"4","key":"440_CR41","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.3747\/co.23.2244","volume":"23","author":"J Amdahl","year":"2016","unstructured":"Amdahl J, Diaz J, Park J, Nakhaipour HR, Delea TE. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 2016;23(4):e340\u201354.","journal-title":"Curr Oncol"},{"issue":"1","key":"440_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","volume":"27","author":"S de Groot","year":"2018","unstructured":"de Groot S, Redekop WK, Versteegh MM, et al. Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Qual Life Res. 2018;27(1):115\u201324.","journal-title":"Qual Life Res"},{"issue":"5","key":"440_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group-6. Medical Decision Making: An International Journal of the Society for Medical Decision Making. 2012;32(5):722\u201332.","journal-title":"Medical Decision Making: An International Journal of the Society for Medical Decision Making"},{"key":"440_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","volume":"48","author":"F Tartari","year":"2016","unstructured":"Tartari F, Santoni M, Burattini L, et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges. Cancer Treat Rev. 2016;48:20\u20134.","journal-title":"Cancer Treat Rev"},{"issue":"31","key":"440_CR45","first-page":"3544","volume":"13","author":"C Hai-tao","year":"2010","unstructured":"Hai-tao C, Jun-qi W, Yong-xing S, Baron A. Survey of the advanced Cancer patients\u2032medical costs in registered hospice care agencies in five provinces and municipalities. Chinese General Practice. 2010;13(31):3544\u20136.","journal-title":"Chinese General Practice"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0440-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0440-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0440-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T15:54:27Z","timestamp":1720799667000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0440-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0440-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"10 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This economic analysis was based on a literature review and modeling techniques; this study did not require approval from an Institutional Research Ethics Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have anything to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"124"}}